The effect of probiotics on glycemic control of women with gestational diabetes mellitus-multicenter, randomized, double blind, placebo controlled-trial

Yefet, Enav; Perlitz, Yuri; Yaakov, Lilach Shavit; Magril, Galit; Vitner, Dana; Zipori, Yaniv; Weiner, Eran; Alon, Ayala Shevach; Paz, Yosef; Nezer, Meirav; Soltsman, Sofia; Nachum, Zohar

doi:10.1016/j.ajog.2021.11.098

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The remaining 18 articles were reviewed in full text, of which 3 had insufficient data. Therefore, a total of 15 RCT articles [8,[12][13][14][15][16][17][18][19][20][21][22][23][24][25] were finally selected for meta-analysis. Error!…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

Effect of probiotics on pregnancy outcomes in gestational diabetes: systematic review and meta-analysis

Wu,

Luan,

et al. 2024

Arch Gynecol Obstet

View full text Add to dashboard Cite

Background: Gestational diabetes is a common complication during pregnancy that can lead to numerous adverse outcomes. Some studies suggest that probiotics may be used to treat gestational diabetes, however, the results remain controversial. We conducted a systematic review and meta-analysis to evaluate the effect of probiotics on blood glucose and pregnancy outcomes in women with gestational diabetes. Methods: A systematic search of PubMed, Embase, and Cochrane databases was performed (start date to August 22, 2023). Primary outcomes included fasting blood sugar (FBS), fasting serum insulin (FSI), homeostasis model assessment of insulin resistance (HOMA-IR), and quantitative insulin sensitivity check index (QUICKI). Secondary outcomes included pregnancy and neonatal outcomes. Results: 15 articles (n = 1006 women) met the inclusion criteria and were included in the analysis. Compared to a placebo, probiotics can decrease FBS (MD -2.58, 95% CI -4.38 to -0.79, p < 0.01), FSI (MD -2.29, 95% CI -3.40 to -1.18, p < 0.01), HOMA-IR (MD -0.56, 95% CI -0.81 to -0.32, p < 0.01), birthweight (MD -101.20, 95% CI -184.62 to -17.77, p = 0.02), neonatal intensive care unit (NICU) (RR 0.60, 95% CI 0.40 to 0.89, p = 0.01), and hyperbilirubinemia (RR 0.31, 95% CI 0.16 to 0.61, p < 0.01), alongside higher QUICKI (MD 0.01, 95% CI 0.00 to 0.01, p < 0.01). However, no other significant results were obtained. Conclusion: Probiotics may improve blood glucose indicators and reduce neonatal hyperbilirubinemia, NICU admissions, and birth weight in women with GDM.

show abstract